Dutch-Belgian biotech company Galapagos will cut about 200 jobs at its European subsidiaries, as a result of a new strategy for the biotech company. The Galapagos Islands reported this Thursday evening, with the quarterly results published.
This action is a result of the new strategy that Galapagos announced on Thursday evening. Its goal is to “accelerate growth and create value by reshaping the way we innovate and do business,” CEO Paul Stoffels said in the press release.
“As a result of our new strategic direction, we plan to reduce our workforce by approximately 200 jobs in our facilities in Europe,” he says. “With this we want to create space for reinvestment in new capabilities and programs in our oncology franchise. This is a difficult but necessary decision, and we will follow all procedures in place with respect to our people.”
Galapagos has a total of 1,357 employees, of which 563 are in Belgium. The press release issued Thursday evening did not say where 200 jobs in Europe will be cut significantly. In addition to Belgium, the company also has employees in France, the Netherlands, Germany, Spain, Italy, Switzerland, Austria, Denmark, Finland, Norway, Sweden, the United Kingdom, Ireland and the United States.
In the new strategy, research and development in important areas of the company – immunology and oncology will become even more important.
This action is a result of the new strategy that Galapagos announced on Thursday evening. Its goal is to “accelerate growth and create value by reshaping the way we innovate and do business,” CEO Paul Stoffels said in the press release. “As a result of our new strategic direction, we plan to reduce our workforce by approximately 200 jobs in our facilities in Europe,” he says. “With this we want to create space for reinvestment in new capabilities and programs in our oncology franchise. This is a difficult but necessary decision, and we will follow all procedures in place with respect to our people.” Galapagos has a total of 1,357 employees, of which 563 are in Belgium. The statement did not say The press release released Thursday evening where 200 jobs in Europe will be significantly cut.In addition to Belgium, the company also has employees in France, the Netherlands, Germany, Spain, Italy, Switzerland, Austria, Denmark, Finland, Norway, Sweden, the United Kingdom, Ireland and the United States.In the new strategy, research and development in the fields will become The mission of the company – immunology and oncology is more important.
